If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
TREATMENT STRATEGIES
HEMATOLOGY
Volume 4 Issue 2
• Acute Leukaemia
• Chronic Lymphocytic Leukaemia
• Hepatic Veno-occlusive Disease
• Leukaemic Stem Cells
• Multiple Myeloma
• Thrombotic Disease
Includes a Review of the 19th Congress of the
European Hematology Association - Milan
Know More. Know Sooner. Know clonoSEQ.
A CLIA-certified clinical diagnostic for monitoring Minimal Residual Disease in blood-based
cancers, clonoSEQ is significantly more sensitive, accurate, and standardized than other common
pathology tests. As a result, hematologists can more accurately detect and track residual
disease at a molecular level and be aware of relapse earlier to improve patient care.
How It Works:
clonoSEQ is a set of CLIA-standardized assays for highly
sensitive (approximately 10-6) detection of MRD in
patients with lymphoid malignancies.
It offers h
TREATMENT STRATEGIES HEMATOLOGY Volume 4 Issue 2
Know More. Know Sooner. Know clonoSEQ. A CLIA-cer
TREATMENT STRATEGIES HEMATOLOGY TreaTMeNT
LymphoTrack Assays TM Enter the next frontier in
3 9 11 15 16 16 17 18 19 20 21 22 22 23 24
Sharpen your view of multiple myeloma with the He
45 49 57 63 69 77
www.tif2014.org 4th Pan-European
Treatment Strategies - Foreword Foreword Di
LIGHTS... CAMERA... ACTION!!! Tune into the late
Treatment Strategies - Congress Review 19thCo
Treatment Strategies - Congress Review that appea
Treatment Strategies - Congress Review the EHA/ES
Treatment Strategies - Congress Review Awards at
Treatment Strategies - Congress Review Strong Pre
Treatment Strategies - Congress Review Assay for
Treatment Strategies - Congress Review Manage
Treatment Strategies - Congress Review Treat
Treatment Strategies - Congress Review Real-Time
Treatment Strategies - Congress Review
Treatment Strategies - Congress Review Innovative
Treatment Strategies - Congress Review Thrombosis
Treatment Strategies - Congress Review Freelite®
Treatment Strategies - Congress Review Intravenou
Treatment Strategies - Congress Review Developmen
Treatment Strategies - Congress Review Researc
Treatment Strategies - Congress Review A Real-tim
Treatment Strategies - Congress Review New Pivota
Treatment Strategies - Congress Review Optimal Ma
Treatment Strategies - Congress Review Poster Syn
Treatment Strategies - Congress Review Poster Syn
Treatment Strategies - Congress Review Associatio
Treatment Strategies - Congress Review Clinical C
Treatment Strategies - Congress Review Poster Syn
Treatment Strategies - Congress Review A Compar
Treatment Strategies - Congress Review EHA 2015..
Treatment Strategies - Congress Review breakfast,
Treatment Strategies - Congress Review
Treatment Strategies - Anti- T-Lymphocyte/Thymocy
Treatment Strategies - Anti- T-Lymphocyte/Thymocy
Treatment Strategies - Anti- T-Lymphocyte/Thymocy
Treatment Strategies - Anti- T-Lymphocyte/Thymocy
Treatment Strategies - Anti- T-Lymphocyte/Thymocy
Treatment Strategies - Anti- T-Lymphocyte/Thymocy
Treatment Strategies - Chronic Lymphocytic Leukae
Treatment Strategies - Chronic Lymphocytic Leukae
patient tolerability. To date, arsenic trioxide i
Treatment Strategies - Chronic Lymphocytic Leukae
Treatment Strategies - Chronic Lymphocytic Leukae
Treatment Strategies - Chronic Lymphocytic Leukae
on miR-181a the most prominent and best character
Treatment Strategies - Chronic Lymphocytic Leukae
gene in AML and patients with higher miR-181a exp
Treatment Strategies - Chronic Lymphocytic Leukae
Treatment Strategies - Chronic Lymphocytic Leukae
www.tif2014.org 4th Pan-European
Treatment Strategies - Chronic Lymphocytic Leukae
Treatment Strategies - Chronic Lymphocytic Leukae
CLL B cells with recombinant HGF we further provi
Treatment Strategies - Chronic Lymphocytic Leukae
Treatment Strategies - Chronic Lymphocytic Leukae
LIGHTS... CAMERA... ACTION!!! Tune into the late
Treatment Strategies - Chronic Lymphocytic Leukae
Treatment Strategies - Chronic Lymphocytic Leukae
as maintenance therapy following first and second
Treatment Strategies - Chronic Lymphocytic Leukae
Treatment Strategies - Chronic Lymphocytic Leukae
LymphoTrack Assays TM Enter the next frontier in
Treatment Strategies - Hepatic Veno-occlusive Dis
Treatment Strategies - Hepatic Veno-occlusive Dis
reduced-intensity conditioning regimens in patien
Treatment Strategies - Hepatic Veno-occlusive Dis
Based upon these promising results, the joint wor
Treatment Strategies - Hepatic Veno-occlusive Dis
Treatment Strategies - Hepatic Veno-occlusive Dis
Sharpen your view of multiple myeloma with the He
Treatment Strategies - Leukaemic Stem Cells
Treatment Strategies - Leukaemic Stem Cells ch
have high ALDH activity and LSCs have low ALDH ac
Treatment Strategies - Leukaemic Stem Cells sh
Treatment Strategies - Leukaemic Stem Cells Ref
Know More. Know Sooner. Know clonoSEQ. A CLIA-cer
Treatment Strategies - Multiple Myeloma MRD
Treatment Strategies - Multiple Myeloma patien
PFS33 and more recently also longer OS;46 by cont
Treatment Strategies - Multiple Myeloma Referen
Treatment Strategies - Multiple Myeloma Molecu
C CAMBRIDGE RESEARCH CENTR
Treatment Strategies - Thrombotic Disease A
Treatment Strategies - Thrombotic Disease Addin
Treatment Strategies - Thrombotic Disease as i
www.tif2014.org 4th Pan-European
Treatment Strategies - Thrombotic Disease R
Treatment Strategies - Thrombotic Disease and
and subsequent increased nitric oxide bioavailabi
Treatment Strategies - Thrombotic Disease Refer
June 28 - July 1, 2015 25th Regional Con
Words of Welcome Dear Friends and Colleagues,
Treatment Strategies - Events Listing Upcom
The Cambridge Research Centre Coppergate House 16